New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
08:08 EDTACTActavis shares should be bought, says Bernstein
Bernstein expects Actavis' cash generation to exceed the industry average by a significant amount. The firm raised its price target on the shares to $250 from $225 and keeps an Outperform rating on the stock.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
18:18 EDTACTGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
08:10 EDTACTActavis confirms appeals court upholds Lo Loestrin Fe patent
Subscribe for More Information
October 22, 2014
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
October 21, 2014
06:44 EDTACTActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
18:51 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
06:28 EDTACTAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTACTValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTACTAllergan not in deal talks with Actavis, CNBC reports
October 16, 2014
17:27 EDTACTNoven files patent infringement suit against Actavis
Subscribe for More Information
15:10 EDTACTAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
08:08 EDTACTActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
08:02 EDTACTIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
October 14, 2014
07:46 EDTACTActavis should be able to mitigate Irish tax downside, says Leerink
Subscribe for More Information
06:03 EDTACTMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
15:12 EDTACTActavis may see modest negative impact from Irish tax change, says BMO Capital
Subscribe for More Information
October 10, 2014
10:20 EDTACTFidelity supports potential merger between Actavis and Allergan, Reuters reports
Subscribe for More Information
07:37 EDTACTActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use